Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Advertisement
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

Medicines In The Environment: EU Moots Action On ‘Green’ Manufacturing, Pack Sizes, Discharges

Stakeholders in the EU are being asked to give their views on ways of addressing the problem of pharmaceuticals posing public health risks when they enter the environment via their manufacture, use and disposal. “Green” manufacturing and design, closer monitoring of discharges and more appropriate pack sizes are among proposals put forward.

Compliance Europe

Don’t Expect Business As Usual From EMA During Transition, Says BIA Head

BIA CEO Steve Bates says life science companies should not expect business as usual during the EMA’s relocation to Amsterdam, but notes that firms and industry associations are “absolutely aligned” on the need for continued close cooperation between the UK and the EU after Brexit. He also warned that firms may be holding back on investments in clinical trials in the UK.

Brexit Clinical Trials

EMA Relocation: EU Approval Delays Cannot Be Ruled Out

Now that the European Medicines Agency knows where it is going after Brexit, the business of preparing for the move can begin. Being able to ensure business continuity during and after the relocation will be highly dependent on the EMA’s ability to retain as many of its current staff as possible. Job losses are expected but it could be some time before it’s clear which business operations will be affected.

Europe Approvals

Amsterdam ‘Ticks Many Of Our Boxes,’ Says EMA Head After Dutch Win Race To Host Agency

London has lost the European Medicines Agency to Amsterdam after the Dutch capital beat Milan in a voting process that ended in the drawing of lots. The EMA welcomed the choice of city, saying the decision met many of its requirements and would help to keep down staff losses and ensure business continuity, but Italy was hugely disappointed at losing out in what amounted to a toss of a coin.

Brexit Netherlands

Amsterdam wins European Medicines Agency After Milan Loses Coin Toss In Tight Race

London has lost the European Medicines Agency to Amsterdam after the Dutch capital beat Milan in a voting process that ended in the drawing of lots. The Italian pharmaceutical industry was understandably disappointed at losing, but the EMA said the decision “ticked a lot of our boxes” and would help to keep down staff losses and ensure business continuity.

Brexit Regulation

French Regulator Wants More Trial Sponsors To Take Part In Pilot Of Future EU Procedures

A French pilot project testing out the future EU clinical trial authorization procedures has borne fruit after the first two years, but the regulator wants many more sponsors to use the pilot so that the country is ready for the new rules in 2019.

Clinical Trials France
See All
Advertisement
UsernamePublicRestriction

Register